Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M450Revenue (TTM) $M120Net Margin (%)7.6Altman Z-Score6.0
Enterprise Value $M459EPS (TTM) $1.3Operating Margin %11.3Piotroski F-Score5
P/E(ttm)52.2Beneish M-Score-2.1Pre-tax Margin (%)11.3Higher ROA y-yY
Price/Book5.410-y EBITDA Growth Rate %0.2Quick Ratio1.6Cash flow > EarningsN
Price/Sales3.95-y EBITDA Growth Rate %16.8Current Ratio2.8Lower Leverage y-yN
Price/Free Cash Flow473y-y EBITDA Growth Rate %51.1ROA % (ttm)8.0Higher Current Ratio y-yY
Dividend Yield %--PEG3.2ROE % (ttm)13.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M6.9ROIC % (ttm)12.5Gross Margin Increase y-yN

Gurus Latest Trades with HSKA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HSKAMario Gabelli 2016-09-30 Reduce$38.41 - $56.16
($49.3)
$ 65.2632%Reduce -3.98%48,200
HSKAMario Gabelli 2015-12-31 Reduce$28.39 - $39.76
($33.34)
$ 65.2696%Reduce -0.40%50,200
HSKAMario Gabelli 2015-09-30 Reduce$28.52 - $35.24
($32.51)
$ 65.26101%Reduce -3.82%50,400
HSKAMario Gabelli 2015-03-31 Reduce$16.32 - $25.94
($21.12)
$ 65.26209%Reduce -1.13%52,400
HSKAMario Gabelli 2012-12-31 Add$7.96 - $9.54
($8.71)
$ 65.26649%Add 29.08%62,135
HSKAMario Gabelli 2012-09-30 Add$7.78 - $11.3
($9.4)
$ 65.26594%Add 50.73%48,135
HSKAMario Gabelli 2012-06-30 Add$10.9 - $12.85
($11.86)
$ 65.26450%Add 56.54%31,935
HSKAMario Gabelli 2011-06-30 Add$6.12 - $9.96
($8.14)
$ 65.26702%Add 31.85%20,700
HSKAMario Gabelli 2011-03-31 Buy $4.79 - $6.83
($5.97)
$ 65.26993%New holding15,700
HSKAMario Gabelli 2010-12-31 Sold Out $0.415 - $0.53
($0.45)
$ 65.2614402%Sold Out0
HSKAMario Gabelli 2010-09-30 Add$4.4 - $6.6
($5.1)
$ 65.261180%Add 14.51%21,070
HSKAMario Gabelli 2010-06-30 Reduce$6.2 - $9
($7.53)
$ 65.26767%Reduce -16.63%18,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HSKA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


HSKA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GORDON G IRWINDirector 2016-11-29Sell3,000$66.11-0.88view
McMahon JohnVP, CFO 2016-11-28Sell1,999$65.64-0.17view
Lippincott RodEVP, Comp. Animal Health Sales 2016-11-22Sell5,000$64.851.05view
Asakowicz SteveEVP, Comp. Animal Health Sales 2016-11-07Sell5,000$617.43view
McGinley Michael JPresi, Biologic. & Pharm. 2016-11-07Sell9,998$60.129view
NAPOLITANO JASON ACOO, CFO, EVP and Secretary 2016-09-01Sell5,000$52.5324.75view
Wilson Kevin S.CEO and President 2016-08-29Sell20,000$51.826.51view
McMahon JohnVP, Fin. Oper. & Controller 2016-08-24Sell137$51.327.74view
Asakowicz SteveEVP, Comp. Animal Health Sales 2016-08-09Sell4,698$52.5524.7view
Wilson Kevin S.CEO and President 2016-08-03Sell30,736$47.3438.42view

Quarterly/Annual Reports about HSKA:

News about HSKA:

Articles On GuruFocus.com
'Kittens Equal Happiness': GAMCO Analyst on Zoetis, Heska, Smuckers Oct 07 2016 
Heska's Still has Room to Run Aug 19 2016 
My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
Heska Corporation: Strong Balance Sheet and Dividend Yield Do Not Compensate for Difficult Business Dec 13 2012 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 5,000 Shares Jun 01 2010 
Heska Corp. (HSKA) CEO Robert B Grieve buys 6,500 Shares May 21 2010 
Weekly CFO Buys Highlight: ZixIt, Global Defense Technology and Systems, FelCor Lodging Trust, Heska Mar 07 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 1,000 Shares Mar 01 2010 

More From Other Websites
AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S. Dec 01 2016
Time to Focus on Heska (HSKA) for Strong Earnings Growth Potential Nov 30 2016
Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor Nov 30 2016
Coverage initiated on Heska Corp by The Benchmark Company Nov 29 2016
Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial Nov 29 2016
Glaxo (GSK) Files Regulatory Application for Shingrix in EU Nov 28 2016
OPKO Health (OPK) Launches Kidney Drug Rayaldee in U.S. Nov 25 2016
Juno's ROCKET Study on Clinical Hold Again, Shares Down Nov 24 2016
Is Heska (HSKA) Stock a Solid Choice Right Now? Nov 23 2016
Allergan's Fibristal Approved in Canada for Label Expansion Nov 22 2016
Agios Presents Data from Dose Expansion Study of AG-120 Nov 21 2016
Apricus Biosciences Aims to Resubmit Vitaros NDA in 2017 Nov 21 2016
Earnings Estimates Moving Higher for Heska (HSKA); Time to Buy? Nov 17 2016
ACADIA Starts Phase II Schizophrenia Study on Pimavanserin Nov 16 2016
Lily's Jardiance Effective in Lowering Cardiovascular Death Nov 14 2016
HESKA CORP Financials Nov 11 2016
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte Nov 11 2016
Sucampo (SCMP) Beats Q3 Earnings & Revenues, Guides Up Nov 10 2016
Zacks.com featured highlights: Heska, Teradyne, Nxstage Medical, Unifi and Rollins Nov 09 2016
Heska (HSKA) Shares March Higher, Can It Continue? Nov 08 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)